Global Oncolytic Virus Therapy Market Trends and Opportunities 2023-2027: Insights for HSV-based Oncolytic Virus, Adenovirus-based Oncolytic Virus, Reovirus, Poxviruses, NDV, and Other Therapy Types
November 01, 2023 08:08 ET
|
Research and Markets
Dublin, Nov. 01, 2023 (GLOBE NEWSWIRE) -- The "Global Oncolytic Virus Therapy Market 2023" report has been added to ResearchAndMarkets.com's offering. The global oncolytic virus therapy market is...
Rising Incidence of Pediatric Diseases and Advances in Research Drive Pediatric Drugs Market Growth
October 25, 2023 09:08 ET
|
Research and Markets
Dublin, Oct. 25, 2023 (GLOBE NEWSWIRE) -- The "Pediatric Drugs Market by Type, by Route of Administration, Distribution Channel, and by Region - Global Forecast to 2023-2033" report has been added...
Advancements in Healthcare and Targeted Therapies Propel Multiple Myeloma Drugs Market Towards $29.6 Billion by 2028
October 25, 2023 08:23 ET
|
Research and Markets
Dublin, Oct. 25, 2023 (GLOBE NEWSWIRE) -- The "Multiple Myeloma Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028" report has been added to ...
Key Segments of the Medication Adherence Market: A Comprehensive Analysis of Patient-Provider Medication Management
October 17, 2023 06:43 ET
|
Research and Markets
Dublin, Oct. 17, 2023 (GLOBE NEWSWIRE) -- The "Medication Adherence Devices - A Global and Regional Analysis: Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's...
Somatostatin Analogs Market revenue to reach USD 10 Billion by 2035, says Research Nester
October 16, 2023 05:30 ET
|
Research Nester
New York, Oct. 16, 2023 (GLOBE NEWSWIRE) -- The global somatostatin analogs market size is slated to expand at ~6% CAGR between 2023 and 2035. The market is poised to garner a revenue of USD 10...
Processa Pharmaceuticals to Present at the ThinkEquity Conference
October 13, 2023 13:08 ET
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, Oct. 13, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next...
Panavance to Present at the BIO Investor Forum
October 05, 2023 07:07 ET
|
Panavance Therapeutics Inc.
BERWYN, PA, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Panavance Therapeutics Inc. (“Panavance” or the “Company”), a clinical-stage pharmaceutical company advancing the development of misetionamide...
Preventing Blood Loss: The Growing Role of Antifibrinolytic Drugs in Gynecology, Surgery, and More
September 22, 2023 09:33 ET
|
Research and Markets
Dublin, Sept. 22, 2023 (GLOBE NEWSWIRE) -- The "Antifibrinolytic Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028" report has been added to ...
Global Controlled Substance Industry Report 2023-2027 & 2032: From Pain Management to ADHD - Exploring the Expanding Applications of Controlled Substances
September 20, 2023 07:28 ET
|
Research and Markets
Dublin, Sept. 20, 2023 (GLOBE NEWSWIRE) -- The "Controlled Substance Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. The global controlled substance market...
Journal of Cellular and Molecular Medicine Publishes Preclinical Data of Panavance’s GP-2250 to treat Pancreatic Cancer
September 12, 2023 07:07 ET
|
Panavance Therapeutics Inc.
Results showed antineoplastic activity in pancreatic tumor cell lines Metabolic and transcriptional findings demonstrate a molecular basis to reduce tumor cell proliferation and induce apoptotic cell...